Some Sun Protection Behaviors Up With History of NMSC

This article originally appeared here.
Share this content:
Some Sun Protection Behaviors Up With History of NMSC
Some Sun Protection Behaviors Up With History of NMSC

MONDAY, May 23, 2016 (HealthDay News) -- Individuals with previous nonmelanoma skin cancer (NMSC) are more likely to engage in certain sun protection behaviors than those without previous NMSC, according to a study published online May 16 in the Journal of the American Academy of Dermatology.

Alexander H. Fischer, from Johns Hopkins University School of Medicine in Baltimore, and colleagues examined whether individuals with previous NMSC engage in better sun protection than individuals with no skin cancer history. Self-reported data were pooled from U.S. non-Hispanic white adults (758 with and 34,161 without previous NMSC).

The researchers found that individuals with versus those without NMSC had higher rates of frequent use of shade (adjusted prevalence odds ratio [aPOR], 1.41; 95 percent confidence interval [CI], 1.16 to 1.71), long sleeves (aPOR, 1.55; 95 percent CI, 1.21 to 1.98), a wide-brimmed hat (aPOR, 1.52; 95 percent CI, 1.24 to 1.87), and sunscreen (aPOR, 2.11; 95 percent CI, 1.73 to 2.59); however, they did not have lower odds of recent sunburn (aPOR, 0.95; 95 percent CI, 0.77 to 1.17). Recent sunburn was inversely associated with age, sun avoidance, and shade, but not with sunscreen use among those with previous NMSC.

"Physicians should emphasize sunburn prevention when counseling patients with previous NMSC, especially younger adults, focusing on shade and sun avoidance over sunscreen," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths